oru.sePublications
Change search
Link to record
Permanent link

Direct link
BETA
Crafoord, Sven
Publications (10 of 21) Show all publications
Barth, H., Crafoord, S., Arnér, K. & Ghosh, F. (2019). Inflammatory responses after vitrectomy with vitreous substitutes in a rabbit model. Graefe's Archives for Clinical and Experimental Ophthalmology, 257(4), 769-783
Open this publication in new window or tab >>Inflammatory responses after vitrectomy with vitreous substitutes in a rabbit model
2019 (English)In: Graefe's Archives for Clinical and Experimental Ophthalmology, ISSN 0721-832X, E-ISSN 1435-702X, Vol. 257, no 4, p. 769-783Article in journal (Refereed) Published
Abstract [en]

PURPOSE: To investigate the inflammatory response of current and future potential vitreous substitutes in an experimental in vivo vitrectomy model.

METHODS: Twenty-five gauge pars plana vitrectomy was performed in the right eye of 60 pigmented rabbits, with subsequent injection of 0.5-1.0 ml of Healaflow® (cross-linked hyaluronic acid, n = 12), Bio-Alcamid® (polyalkylimide, n = 8), silicone oil (n = 12), or balanced saline solution (BSS, n = 28). Postoperative clinical evaluation was performed; and the rabbits were sacrificed at 1 day, 1 week, or 1 month. The eyecups were then examined macroscopically; the retinas sectioned and stained with hematoxylin and eosin (Htx), and immunohistochemically labeled for glial fibrillary acidic protein (GFAP), CD45, galectin-3, CD68, and CD20. Unoperated left eyes from treated animals as well as eyes from untreated animals were used as controls.

RESULTS: Vitrectomy without major complications was achieved in 46/60 eyes. The remaining 14 eyes were analyzed separately. One eye developed endophthalmitis after 1 week and was excluded. Eyes treated with Healaflow®, silicone oil, and BSS had a comparable appearance macroscopically and in Htx-stained sections, whereas Bio-Alcamid®-injected eyes exhibited increased macroscopic inflammation and severely affected retinas. GFAP upregulation was present in all treatment groups, most prominent in eyes treated with Bio-Alcamid® and silicone oil. Upregulation of CD45 and CD68 in the inner retina and vitreous space was most prominent with Bio-Alcamid® treatment, and these eyes together with their silicone oil-treated counterparts also displayed a stronger upregulation of CD20-labeled cells compared with remaining groups. General upregulation of galectin-3, mainly in the inner retina, was found in all groups. In eyes with perioperative complications, labeling of CD45, CD68, and especially GFAP was comparably high.

CONCLUSIONS: We here describe differences in the postsurgery inflammatory profiles of existing and potential vitreous substitutes. Bio-Alcamid® and silicone oil display severe signs of gliosis and inflammation, whereas Healaflow® elicits minimal reactions comparable with BSS, highlighting its potential application as a vitreous substitute in a future clinical setting.

Place, publisher, year, edition, pages
Springer, 2019
Keywords
Hyaluronic acid, Hydrogel, Methods, Vitreoretinal surgery, Vitreous, Vitreous substitute
National Category
Ophthalmology
Identifiers
urn:nbn:se:oru:diva-71653 (URN)10.1007/s00417-019-04242-0 (DOI)000462942600013 ()30656473 (PubMedID)
Funder
Swedish Research Council, 90247201
Note

Funding Agency:

Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse

Available from: 2019-01-22 Created: 2019-01-22 Last updated: 2019-06-18Bibliographically approved
Barth, H., Crafoord, S. & Ghosh, F. K. (2018). Developing a retinal detachment model for in vivo testing of vitreous substitutes with repeated pars plana vitrectomy. Paper presented at Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO 2018), Honolulu, Hawaii, USA, April 28 - May 3, 2018. Investigative Ophthalmology and Visual Science, 59(9), Article ID 5941.
Open this publication in new window or tab >>Developing a retinal detachment model for in vivo testing of vitreous substitutes with repeated pars plana vitrectomy
2018 (English)In: Investigative Ophthalmology and Visual Science, ISSN 0146-0404, E-ISSN 1552-5783, Vol. 59, no 9, article id 5941Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
Lippincott-Raven Publishers, 2018
National Category
Ophthalmology
Identifiers
urn:nbn:se:oru:diva-69253 (URN)000442932807077 ()
Conference
Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO 2018), Honolulu, Hawaii, USA, April 28 - May 3, 2018
Funder
Swedish Research Council, 90247201Wallenberg Foundations, MMW 2011.0009
Note

Funding Agencies:

Faculty of Medicine, University of Lund

Foundation of Debilitating Eye Diseases in former Malmohus County  

Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse 

Available from: 2018-10-04 Created: 2018-10-04 Last updated: 2018-10-04Bibliographically approved
Makdoumi, K., Nilsson, T. K. & Crafoord, S. (2017). Levels of beta-trace protein in optic disc pit with macular detachment. Acta Ophthalmologica, 95(8), 815-819
Open this publication in new window or tab >>Levels of beta-trace protein in optic disc pit with macular detachment
2017 (English)In: Acta Ophthalmologica, ISSN 1755-375X, E-ISSN 1755-3768, Vol. 95, no 8, p. 815-819Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: To report beta-trace protein (βTP) levels in the subretinal fluid (SRF) of four patients with a macular detachment associated with optic disc pit (ODP).

METHODS: Four patients with a serous retinal detachment involving the macula was operated by pars plana vitrectomy (PPV) with C2 F6 gas tamponade and peeling of internal limiting membrane (ILM). Patients with a follow-up period exceeding one year postoperatively were included in the study. The SRF was drained using a fine cannula without laser photocoagulation, and the samples were analysed using particle-enhancing nephelometry. The levels of βTP were compared to 20 routine cerebrospinal fluid (CSF) samples.

RESULTS: In four of the five samples from SRF had relatively low βTP levels, with a mean concentration of 6.6 mg/l (range 2.0 to 23.1 mg/l) compared to 16.0 mg/l (range 6.3-26.8 mg/l) in CSF. The only SRF sample within the range corresponding to normal CSF was the first sample from patient 4, and the analysis of the renewed aspirate during the second operation was 2.8 mg/l. Postoperatively, the regression of SRF was slow, but regression of SRF in the foveal region took place in all cases; however, visual acuity (VA) was improved in only half of the patients.

CONCLUSION: The results from the analysed SRF regarding βTP concentration in these patients indicate that the SRF in ODP is not identical to CSF, as the concentrations of βTP differ.

Place, publisher, year, edition, pages
Wiley-Blackwell Publishing Inc., 2017
Keywords
beta trace, beta-trace protein, optic disc pit, β-trace protein
National Category
Ophthalmology
Identifiers
urn:nbn:se:oru:diva-62465 (URN)10.1111/aos.13527 (DOI)000417645900036 ()28926186 (PubMedID)2-s2.0-85030124493 (Scopus ID)
Available from: 2017-12-04 Created: 2017-12-04 Last updated: 2018-08-11Bibliographically approved
Barth, H., Crafoord, S., Andréasson, S. & Ghosh, F. (2016). A cross-linked hyaluronic acid hydrogel (Healaflow(®)) as a novel vitreous substitute. Graefe's Archives for Clinical and Experimental Ophthalmology, 254(4), 697-703
Open this publication in new window or tab >>A cross-linked hyaluronic acid hydrogel (Healaflow(®)) as a novel vitreous substitute
2016 (English)In: Graefe's Archives for Clinical and Experimental Ophthalmology, ISSN 0721-832X, E-ISSN 1435-702X, Vol. 254, no 4, p. 697-703Article in journal (Refereed) Published
Abstract [en]

Purpose: Vitrectomy requires the substitution of the natural vitreous, as well as tamponading of retinal breaks. Clinically available alternatives such as gas and silicone oil have side effects such as inflammation, secondary glaucoma, cataract, and a need for head posturing. In this study, a hydrogel of cross-linked sodium hyaluronic acid (Healaflow(®)) is evaluated for use as a novel vitreous substitute.

Methods: A combined 25-20-gauge pars plana vitrectomy with posterior vitreous detachment was performed in the right eye of twelve pigmented rabbits, with subsequent injection of approximately 1 ml Healaflow(®). Clinical evaluation, measurement of intraocular pressure (IOP), and full-field ERG were performed postoperatively. The rabbits were sacrificed at different time-points between 42 and 105 days. After enucleation, the eyes were examined macroscopically, photographed, and prepared for histological examination with routine microscopy and immunohistochemistry.

Results: Healaflow(®) was successfully used with standard surgical procedures and remained translucent but did lose most of its viscosity during the postoperative period. One rabbit was lost due to unrelated causes. In two eyes iatrogenic partial retinal detachments were seen, and in two eyes significant cataract developed due to intra-operative complications. ERG-recordings revealed no toxic effect on rod or cone function. Routine microscopy and immunohistochemistry demonstrated normal morphology with some Müller cell activation (up-regulation of glial acidic fibrillary protein, GFAP) compared to unoperated eyes and no significant DNA-fragmentation (TUNEL-assay).

Conclusions: Healaflow® did not affect retinal morphology or function negatively during long-term use as a vitreous substitute, making it highly interesting in this setting. An estimated retention time of a few weeks suggests potential for use as a short-term tamponade. Future work will include an increased ratio of cross-linking to prolong the structural integrity of the gel.

Place, publisher, year, edition, pages
Springer, 2016
Keywords
Vitreous substitute, vitreoretinal surgery, hyaluronic acid, immunohistochemistry
National Category
Ophthalmology
Identifiers
urn:nbn:se:oru:diva-49649 (URN)10.1007/s00417-015-3256-z (DOI)000372608100012 ()26743755 (PubMedID)2-s2.0-84961215909 (Scopus ID)
Funder
Swedish Research Council
Note

Funding Agencies:

Faculty of Medicine, University of Lund

Foundation of Debilitating Eye Diseases in former Malmohus County

Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse

Wallenberg foundation

Available from: 2016-04-13 Created: 2016-04-05 Last updated: 2018-07-10Bibliographically approved
Barth, H., Crafoord, S., O'Shea, T. M., Pritchard, C. D., Langer, R. & Ghosh, F. (2014). A new model for in vitro testing of vitreous substitute candidates. Graefe's Archives for Clinical and Experimental Ophthalmology, 252(10), 1581-1592
Open this publication in new window or tab >>A new model for in vitro testing of vitreous substitute candidates
Show others...
2014 (English)In: Graefe's Archives for Clinical and Experimental Ophthalmology, ISSN 0721-832X, E-ISSN 1435-702X, Vol. 252, no 10, p. 1581-1592Article in journal (Refereed) Published
Abstract [en]

Purpose: To describe a new model for in vitro assessment of novel vitreous substitute candidates.

Methods: The biological impact of three vitreous substitute candidates was explored in a retinal explant culture model; a polyalkylimide hydrogel (Bio-Alcamid (R)), a two component hydrogel of 20 wt.% poly (ethylene glycol) in phosphate buffered saline (PEG) and a cross-linked sodium hyaluronic acid hydrogel (Healaflow (R)). The gels where applied to explanted adult rat retinas and then kept in culture for 2, 5 and 10 days. Gel-exposed explants were compared with explants incubated under standard tissue culture conditions. Cryosections of the specimens were stained with hematoxylin and eosin, immunohistochemical markers (GFAP, Vimentin, Neurofilament 160, PKC, Rhodopsin) and TUNEL.

Results: Explants kept under standard conditions as well as PEG-exposed explants displayed disruption of retinal layers with moderate pyknosis of all neurons. They also displayed moderate labeling of apoptotic cells. Bio-Alcamid (R)-exposed explants displayed severe thinning and disruption of retinal layers with massive cell death. Healaflow (R)-treated explants displayed normal retinal lamination with significantly better preservation of retinal neurons compared with control specimens, and almost no signs of apoptosis. Retinas exposed to Healaflow (R) and retinas kept under standard conditions showed variable labeling of GFAP with generally low expression and some areas of upregulation. PEG-exposed retinas showed increased GFAP labeling and Bio-Alcamid (R)-exposed retinas showed sparse labeling of GFAP.

Conclusions: Research into novel vitreous substitutes has important implications for both medical and surgical vitreoretinal disease. The in vitro model presented here provides a method of biocompatibility testing prior to more costly and cumbersome in vivo experiments. The explant culture system imposes reactions within the retina including disruption of layers, cell death and gliosis, and the progression of these reactions can be used for comparison of vitreous substitute candidates. Bio-Alcamid (R) had strong adverse effects on the retina which is consistent with results of prior in vivo trials. PEG gel elicits reactions similar to the control retinas whereas Healaflow (R) shows protection from culture-induced trauma indicating favorable biocompatibility.

Place, publisher, year, edition, pages
Hedidelberg, Germany: Springer, 2014
Keywords
Vitreous substitute, Immunohistochemistry, Retinal culture, Vitreoretinal surgery, Hyaluronic acid, Polyethylene oxide, Polyal kylimide
National Category
Ophthalmology
Research subject
Medicine
Identifiers
urn:nbn:se:oru:diva-39809 (URN)10.1007/s00417-014-2714-3 (DOI)000344631600009 ()25059475 (PubMedID)2-s2.0-84904522229 (Scopus ID)
Funder
Swedish Research Council
Note

Funding Agencies:

Faculty of Medicine, University of Lund

Princess Margareta's Foundation for Blind Children

Wallenberg Foundation

Sir General John Monash Scholarship

In Vivo Therapeutics Corporation

Available from: 2014-12-16 Created: 2014-12-16 Last updated: 2018-09-12Bibliographically approved
Bäckman, A., Makdoumi, K., Mortensen, J. & Crafoord, S. (2014). The efficiency of cross-linking methods in eradication of bacteria is influenced by the riboflavin concentration and the irradiation time of ultraviolet light. Acta Ophthalmologica, 92(7), 656-661
Open this publication in new window or tab >>The efficiency of cross-linking methods in eradication of bacteria is influenced by the riboflavin concentration and the irradiation time of ultraviolet light
2014 (English)In: Acta Ophthalmologica, ISSN 1755-375X, E-ISSN 1755-3768, Vol. 92, no 7, p. 656-661Article in journal (Refereed) Published
Abstract [en]

Purpose: To determine bacterial eradication using numerous riboflavin concentrations and different ultraviolet light A (UVA) radiant and exposure time in an experimental model.

Methods: Dilutions of Staphylococcus epidermidis were mixed with riboflavin at varying concentrations (0.007-0.09%). Effects on bacterial growth were evaluated after 0, 3, 6, 30 and 60min of UVA exposure (irradiance 30 and 3mW/cm(2)). Standard settings of UVA were compared with high-power UVA approach. Different fluid thicknesses of the exposed dilutions were also examined to improve the model.

Results: Bacterial eradication (%) was increased after 60 compared with 30min of UVA exposure for concentrations of 0.03-0.07% but not for 0.09% riboflavin. There was a significant difference between the efficacy between 0.03 and 0.09% and eradication dropped from 80% to 50% (p=0.01). A correlation could be calculated for the amount of riboflavin at 60min of UVA and the ability to kill bacteria (p=0.01). The antibacterial effect was more pronounced when the tested bacterial suspension thickness was reduced. High-power UVA method was less potent in microbial elimination, eradicating only 60% of bacteria after 6min versus 97-99% after 60min in the low-power setting, compared with respective controls (p=0.02).

Conclusions: In these in vitro experiments, a longer UVA exposure time in combination with lower riboflavin levels were found to be favourable in killing bacteria as compared to the standard cross-linking settings. Further studies are needed to evaluate the clinical relevance of these findings.

Place, publisher, year, edition, pages
Hoboken, USA: John Wiley & Sons, 2014
Keywords
Bacteria, cross-linking, exposure time, riboflavin, UVA
National Category
Ophthalmology
Identifiers
urn:nbn:se:oru:diva-39452 (URN)10.1111/aos.12301 (DOI)000344162700030 ()25493311 (PubMedID)2-s2.0-84887264034 (Scopus ID)
Note

Funding Agency:

Örebro University Hospital (Sweden) - Research Funds OLL-120691

Available from: 2014-12-10 Created: 2014-12-10 Last updated: 2018-08-29Bibliographically approved
Crafoord, S., Ghosh, F. & Sebag, J. (2014). Vitreous biochemistry and artificial vitreous (1ed.). In: Jerry Sebag MD, FACS, FRCOphth, FARVO (Ed.), Vitreous: in Health and Disease (pp. 81-92). New York, USA: Springer
Open this publication in new window or tab >>Vitreous biochemistry and artificial vitreous
2014 (English)In: Vitreous: in Health and Disease / [ed] Jerry Sebag MD, FACS, FRCOphth, FARVO, New York, USA: Springer, 2014, 1, p. 81-92Chapter in book (Other academic)
Place, publisher, year, edition, pages
New York, USA: Springer, 2014 Edition: 1
Keywords
Vitreous, biochemistry, collagen, hyaluronan, artificial vitreous, hydrogels, polyalkylimide, polyethylene glycol, cross-linked hyaluronic acid hydrogels
National Category
Medical and Health Sciences Ophthalmology
Research subject
Medicine
Identifiers
urn:nbn:se:oru:diva-39959 (URN)10.1007/978-1-4939-1086-1 (DOI)978-1-4939-1085-4 (ISBN)978-1-4939-1086-1 (ISBN)
Available from: 2014-12-22 Created: 2014-12-22 Last updated: 2018-06-14Bibliographically approved
Makdoumi, K., Bäckman, A., Mortensen, J., Magnuson, A. & Crafoord, S. (2013). Comparison of UVA- and UVA/riboflavin-induced growth inhibition of Acanthamoeba Castellanii. Graefe's Archives for Clinical and Experimental Ophthalmology, 251(2), 509-514
Open this publication in new window or tab >>Comparison of UVA- and UVA/riboflavin-induced growth inhibition of Acanthamoeba Castellanii
Show others...
2013 (English)In: Graefe's Archives for Clinical and Experimental Ophthalmology, ISSN 0721-832X, E-ISSN 1435-702X, Vol. 251, no 2, p. 509-514Article in journal (Refereed) Published
Abstract [en]

Purpose To investigate whether ultraviolet light (UVA) at 365 nm can inhibit/eliminate Acanthamoeba growth and if riboflavin would potentiate such an association.

Method: Acanthamoeba castellanii in a fluid medium with a concentration of approximately 1.7 x 10(4) protozoa/ml were prepared with (0.01 %) and without riboflavin. Exposure of UVA (dose 5.475 J/cm(2)) took place twice, with each illumination period followed by culturing of 10 mu l in peptone yeast-extract glucose (PYG) medium for 7 days. Every suspension prepared had a non-exposed control solution. Determination of Acanthamoeba was conducted daily, by count in Burker chamber days 4 through 7 after exposure. Statistical analysis was done by repeated-measurement ANOVA and post-hoc analysis for unpaired samples.

Results: The exposure of ultraviolet light resulted in an inhibited growth of Acanthamoeba compared to the non-exposed solutions, with a statistically significant reduction over time (p = 0.0003). The addition of riboflavin did not amplify the effect, and there were no tendencies for an interaction effect between UVA and riboflavin. The antiprotozoal effect of the UVA wavelength, utilized in CXL, is solely mediated by ultraviolet light, and riboflavin does not seem to amplify the antimicrobial efficacy.

Place, publisher, year, edition, pages
New York, USA: Springer, 2013
Keywords
Acanthamoeba, Acanthamoeba castellanii, UV, UVA, Riboflavin, Keratitis, Growth inhibition
National Category
Ophthalmology
Research subject
Medicine
Identifiers
urn:nbn:se:oru:diva-38720 (URN)10.1007/s00417-012-2176-4 (DOI)000314683200012 ()23079692 (PubMedID)2-s2.0-84877108959 (Scopus ID)
Note

Funding agency:

Orebro University Hospital, Sweden: OLL-1578 , OLL-120691 

Available from: 2014-11-18 Created: 2014-11-18 Last updated: 2018-05-22Bibliographically approved
Slidsborg, C., Lyng Forman, J., Fielder, A. R., Crafoord, S., Baggesen, K., Bangsgaard, R., . . . La Cour, M. (2012). Experts do not agree when to treat retinopathy of prematurity based on plus disease. British Journal of Ophthalmology, 96(4), 549-553
Open this publication in new window or tab >>Experts do not agree when to treat retinopathy of prematurity based on plus disease
Show others...
2012 (English)In: British Journal of Ophthalmology, ISSN 0007-1161, E-ISSN 1468-2079, Vol. 96, no 4, p. 549-553Article in journal (Refereed) Published
Abstract [en]

Objectives: To investigate inter-reader agreement on five severity levels of central vascular changes (none, mild, moderate, severe pre-plus disease, plus disease) and aggressive posterior retinopathy of prematurity (ROP), and to see whether an unintended shift in indication for treatment occurred.

Methods: Four international ROP readers participated. Before the grading of the photographs, the readers were informed that a high proportion of advanced ROP cases were included. In total, 243 photographs/948 quadrants were available from 136 infants. As a standard series of photographs was available, grading was performed under optimised conditions.

Results: The four readers agreed on the quadrant scores of only 70 (7.38%) of the 948 quadrants-that is, on 1, 5, 15, 4 and 45 quadrants for scores 0, 1, 2, 3 and 4, respectively. The mean scores differed systematically between the readers (permutation test, p<0.0001). Agreement on presence of aggressive posterior ROP from all four readers was not obtained for any of the photographs. Readers scored plus disease in at least two quadrants in 95.5% of the eyes for which treatment was indicated. All four readers agreed on the scoring of indication for treatment for 195 eyes (80.2%); however, treatment was only recommended in 18 (7.4%) eyes. One reader was found to differ systematically from the others in indicating treatment (Rasch analysis; p=0.0001). Finally, a significant shift in indication for treatment occurred between birth period 2000-2002 and 2003-2006 (Mann-Whitney rank sum test, p<0.001).

Conclusions: Inter-reader agreement on central vascular changes is poor, especially when based on more than two rating categories. The subjective nature of diagnosing such vascular changes possibly resulted in earlier treatment of preterm infants in Denmark over the entire study period (1997-2006). The recent increased incidence of treated infants in Denmark is, at least in part, explained by a significant shift in indication for treatment.

Place, publisher, year, edition, pages
London, United Kingdom: B M J Publishing Group, 2012
National Category
Medical and Health Sciences Ophthalmology
Research subject
Medicine
Identifiers
urn:nbn:se:oru:diva-22623 (URN)10.1136/bjophthalmol-2011-300573 (DOI)000301938700019 ()22174097 (PubMedID)2-s2.0-84858340878 (Scopus ID)
Note

Funding Agencies:

Danish Eye Health Society 

Bagenkop Nielsens Myopi- and Eye Foundation 

VELUX Foundation

Aase and Ejnar Danielsens Foundation

Dagmar Marshalls Foundation

Direktor Jacob Madsen and Hustru Olga Madsens Foundation 

P. A. Messerschmidt and Hustrus Foundation 

Available from: 2012-04-23 Created: 2012-04-23 Last updated: 2017-12-07Bibliographically approved
Makdoumi, K., Mortensen, J., Sorkhabi, O., Malmvall, B.-E. & Crafoord, S. (2012). UVA-riboflavin photochemical therapy of bacterial keratitis: a pilot study. Graefe's Archives for Clinical and Experimental Ophthalmology, 250(1), 95-102
Open this publication in new window or tab >>UVA-riboflavin photochemical therapy of bacterial keratitis: a pilot study
Show others...
2012 (English)In: Graefe's Archives for Clinical and Experimental Ophthalmology, ISSN 0721-832X, E-ISSN 1435-702X, Vol. 250, no 1, p. 95-102Article in journal (Refereed) Published
Abstract [en]

Background: The aim of this work as to investigate the photochemical interaction used in corneal crosslinking (CXL) as the primary therapy for bacterial keratitis.

Methods: A prospective non-randomized study was conducted including 16 patients with a clinical diagnosis of bacterial keratitis. No patient had any prior antibiotic treatment for the current infection. Photography and microbial culturing of the infected cornea were performed. Riboflavin was topically administered for 20 min and ultraviolet light (UVA) exposure settings for treatment of keratoconus were used. After the procedure, clinical examinations were done at least once daily until signs of improvement had been established. The frequency of examinations was thereafter reduced. Antibiotic therapy was initiated if infectious progression was suspected. The trial was registered at ISCRTN.org (no: 21432643).

Results: All eyes responded to the photochemical treatment with improvement in symptoms and signs of reduced inflammation. Epithelial healing was achieved in all cases. Antibiotic administration was necessary in two cases. One patient required a human amniotic membrane transplant.

Conclusions: This trial illustrates that photosensitization of riboflavin using UVA at 365 nm has the potential to induce healing in patients with microbial keratitis. The results from the treatment of these 16 patients with corneal ulcers indicate that UVA-riboflavin photochemical therapy merits a controlled study in order to assess its efficacy and safety compared to antibiotics.

Place, publisher, year, edition, pages
New York, USA: Springer, 2012
Keywords
UV, UVA, ultraviolet, riboflavin, CXL, keratitis, pilot study
National Category
Surgery Medical and Health Sciences
Research subject
Surgery; Medicine
Identifiers
urn:nbn:se:oru:diva-20752 (URN)10.1007/s00417-011-1754-1 (DOI)000299371000012 ()21874347 (PubMedID)2-s2.0-84857359468 (Scopus ID)
Note

Funding Agencies:

Örebro University Hospital (Sweden) OLL-57221

Futurum, the Academy of Health Care, Jonkoping (Sweden)

Available from: 2012-01-09 Created: 2012-01-09 Last updated: 2018-05-08Bibliographically approved
Organisations

Search in DiVA

Show all publications